Synthetic Cathinones

"Synthetic cathinones are related to the parent compound cathinone (Figure 1), one of the psychoactive principals in khat (Catha edulis Forsk). Cathinone derivatives are the β-keto (βk) analogues of a corresponding phenethylamine. The group includes several substances that have been used as active pharmaceutical ingredients (API) of medicinal products, e.g. amfepramone (diethylpropion; Figure 2). Since the mid-2000s, unregulated ring-substituted cathinone derivatives have appeared in the European recreational drugs market.

Synthetic Cannabinoids

"Synthetic cannabinoids, also known as synthetic cannabinoid receptor agonists, are a group of drugs that mimic the effects of a substance found in cannabis called tetrahydrocannabinol (THC). THC is responsible for many of the psychoactive effects of cannabis which give that feeling of being ‘stoned’ or ‘high’ (Gaoni and Mechoulam, 1964; Huestis et al., 2001; Pertwee, 2005a; Pertwee, 2014). These effects are caused by activating a receptor in the brain called the cannabinoid receptor type 1 (CB1 receptor) (Huestis et al., 2001; Pertwee, 2014).

Number of New Psychoactive Substances Continues to Grow

"Since around 2008, there has been a dramatic growth in the NPS market as globalisation and new technologies, such as the internet, have allowed them to be produced, sold and supplied on an industrial scale. Between 2009 and 2018, 119 countries and territories reported the emergence of 892 different NPS to UNODC, through the UNODC Early Warning Advisory on NPS (UNODC, 2019b). In Europe, more than 730 NPS have appeared on the drug market since monitoring began in 1997, with around 90 % of these being detected between 2008 and 2018 (EMCDDA, 2019b).

"New" Psychoactive Substances Are Not Necessarily New

"In the operating guidelines on the early warning system, EMCDDA [European Monitoring Centre on Drugs and Drug Addiction] made it explicit that 'the term ‘new’ did not refer to newly invented, but rather ‘newly misused’' substances as 'most of the drugs in question were first created many years ago.'20 In fact, investigations into the potential use of piperazines as anthelmintic have been reported in scientific literature since the early 1950s.21 Yet they only started to emerge as a health problem in several countries in the decade 2001-2010.

Prevalence of Past-Month Drug Use in Norway

"The findings on drug use are based partly on positive findings from urine tests and partly on reported use during the last 30 days. The levels are overall quite similar to 2012. A proportion of 10 per cent reported having used an illegal morphine substance during the past month, 33 per cent cannabis, 16 per cent stimulants and as many as 42 per cent benzodiazepines. This figure includes both prescribed and non-prescribed benzodiazepines. Twenty-five per cent of all patients report having been prescribed the drug by a doctor. In other words, the others must have used illegal sources.

Estimated Prevalence of Amphetamine and Methamphetamine Use in the EU

"It is estimated that 12.3 million adults in the European Union (aged 15-64), or 3.7% of this age group, have used amphetamines at least once in their lifetime. Figures from the 26 countries that report a survey between 2014 and 2018 suggest that 1.4 million (1.2%) young adults (aged 15-34) used amphetamines during the last year, with national prevalence estimates ranging from zero in Portugal to 3% in Finland (Figure 13). The available data suggest that over the longer term, prevalence levels have been relatively stable in most countries.

Prevalence of Heroin and Illegal Opioid Use in the EU

"The prevalence of high-risk opioid use among adults (15-64) is estimated at 0.4 % of the EU population, equivalent to 1.3 million high-risk opioid users in 2018. At national level, prevalence estimates of high-risk opioid use range from less than 1 to more than 8 users per 1 000 population aged 15-64 (Figure 27). The five most populous countries in the European Union (Germany, Spain, France, Italy, United Kingdom), account for three quarters (75 %) of this estimate.